Antiprotozoal Activity Profiling of Approved Drugs: A Starting Point toward Drug Repositioning.

Abstract

Neglected tropical diseases cause significant morbidity and mortality and are a source of poverty in endemic countries. Only a few drugs are available to treat diseases such as leishmaniasis, Chagas' disease, human African trypanosomiasis and malaria. Since drug development is lengthy and expensive, a drug repurposing strategy offers an attractive fast-track approach to speed up the process. A set of 100 registered drugs with drug repositioning potential for neglected diseases was assembled and tested in vitro against four protozoan parasites associated with the aforementioned diseases. Several drugs and drug classes showed in vitro activity in those screening assays. The results are critically reviewed and discussed in the perspective of a follow-up drug repositioning strategy where R&D has to be addressed with limited resources.

• Authors: Marcel Kaiser, Pascal Mäser, Leela Pavan Tadoori, Jean-Robert Ioset, Reto Brun
• Journal: PloS one (PLoS One) Vol. 10 Issue 8 Pg. e0135556 ( 2015) ISSN: 1932-6203 [Electronic] United States
• PMID: 26270335 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antiprotozoal Agents

Topics

• Animals
• Antiprotozoal Agents (pharmacology, therapeutic use)
• Cells, Cultured
• Chagas Disease (drug therapy)
• Disease Models, Animal
• Drug Evaluation, Preclinical
• Drug Repositioning (methods)
• Humans
• Leishmania donovani (drug effects)
• Leishmaniasis (drug therapy)
• Macrophages, Peritoneal (drug effects, parasitology)
• Malaria (drug therapy)
• Mice
• Neglected Diseases (drug therapy)
• Plasmodium falciparum (drug effects)
• Trypanosoma brucei rhodesiense (drug effects)
• Trypanosoma cruzi (drug effects)
• Trypanosomiasis, African (drug therapy)